Physician profile
Jill R Toliver
NPI 1518923499
$116,339.23
in general payments reported to CMS, 2019-2025
9 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,690 · 2022: $9,260 · 2023: $15K · 2024: $20K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $16K · Travel and Lodging: $12K · Food and Beverage: $2,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,457.10 |
| Consulting Fee | $15,956.50 |
| Travel and Lodging | $12,320.27 |
| Food and Beverage | $2,655.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $46,529.89 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $44,393.72 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $14,863.58 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $10,407.77 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $56.11 | 2021-2024 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $48.10 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $14.59 | 2025 | Auvelity |
| Sage Therapeutics, LLC | $13.61 | 2025 | Zurzuvae |
| Lundbeck LLC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Toliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.